Selux Receives FDA Clearance for its Rapid Antibiotic Susceptibility Test (AST) System

Selux Receives FDA Clearance for its Rapid Antibiotic Susceptibility Test (AST) SystemSelux Receives FDA Clearance for its Rapid Antibiotic Susceptibility Test (AST) System

What You Should Know:

Selux Diagnostics has been granted 510(k) clearance from the US FDA for its Next Generation Phenotyping (NGP) System — a rapid antibiotic susceptibility (AST) testing platform able to determine a bacteria’s susceptibility to a specific panel of antimicrobial agents.

– In vitro antimicrobial resistance test enables clinical labs to deliver targeted therapeutic results days faster than the current standard of care, clearing the path for personalized antibiotic therapies.